196 related articles for article (PubMed ID: 34730214)
1. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
Lai S; Perrotta AM; Bagordo D; Mazzaferro S; Menè P; Gigante A; Tinti F; Galani A; Cianci R
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6333-6338. PubMed ID: 34730214
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Heart Rate Variability in Autosomal Dominant Polycystic Kidney Disease.
Lai S; Mangiulli M; Perrotta AM; Di Lazzaro Giraldi G; Testorio M; Rosato E; Cianci R; Gigante A
Kidney Blood Press Res; 2019; 44(5):1142-1148. PubMed ID: 31550720
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
Rahbari-Oskoui F; Williams O; Chapman A
Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
[TBL] [Abstract][Full Text] [Related]
4. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
Lai S; Petramala L; Mastroluca D; Petraglia E; Di Gaeta A; Indino E; Panebianco V; Ciccariello M; Shahabadi HH; Galani A; Letizia C; D'Angelo AR
Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
[TBL] [Abstract][Full Text] [Related]
5. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.
Barrett BJ; Foley R; Morgan J; Hefferton D; Parfrey P
Kidney Int; 1994 Oct; 46(4):1118-23. PubMed ID: 7861706
[TBL] [Abstract][Full Text] [Related]
6. The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease.
Ermurat S; Güllülü M; Sarandöl E
Ir J Med Sci; 2022 Dec; 191(6):2777-2783. PubMed ID: 35067861
[TBL] [Abstract][Full Text] [Related]
7. Hypertension in autosomal dominant polycystic kidney disease.
Chapman AB; Stepniakowski K; Rahbari-Oskoui F
Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
[TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular risk in polycystic kidney disease].
Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
[TBL] [Abstract][Full Text] [Related]
9. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Schrier RW
J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors.
Martinez-Vea A; Valero FA; Bardaji A; Gutierrez C; Broch M; Garcia C; Richart C; Oliver JA
Am J Nephrol; 2000; 20(3):193-200. PubMed ID: 10878400
[TBL] [Abstract][Full Text] [Related]
11. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
Wang D; Strandgaard S
J Hypertens; 1997 Sep; 15(9):925-33. PubMed ID: 9321739
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular complications in autosomal dominant polycystic kidney disease.
Ecder T
Curr Hypertens Rev; 2013 Feb; 9(1):2-11. PubMed ID: 23971638
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression.
Hian CK; Lee CL; Thomas W
Nephron; 2016; 134(2):59-63. PubMed ID: 27476173
[TBL] [Abstract][Full Text] [Related]
14. Impairment of heart rate recovery index in autosomal-dominant polycystic kidney disease patients without hypertension.
Orscelik O; Kocyigit I; Baran O; Kaya C; Dogdu O; Zengin H; Karadavut S; Gedikli O; Kut E; Duran M; Calapkorur B; Tokgoz B; Kaya MG
Blood Press; 2012 Oct; 21(5):300-5. PubMed ID: 22545873
[TBL] [Abstract][Full Text] [Related]
15. Urinary renin-angiotensin markers in polycystic kidney disease.
Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
[TBL] [Abstract][Full Text] [Related]
16. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
Ecder T; Schrier RW
Nat Rev Nephrol; 2009 Apr; 5(4):221-8. PubMed ID: 19322187
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease.
Wang D; Iversen J; Wilcox CS; Strandgaard S
Kidney Int; 2003 Oct; 64(4):1381-8. PubMed ID: 12969157
[TBL] [Abstract][Full Text] [Related]
19. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
Barendregt JN; Florijn KW; Muizert Y; Chang PC
Nephrol Dial Transplant; 1995; 10(8):1332-41. PubMed ID: 8538923
[TBL] [Abstract][Full Text] [Related]
20. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
